Navigation Links
Cogane Data Presented at ‘11th International Congress of,Parkinson’s Disease and Disorders’

onal food company whose product leads are generated from medicinal plants. The Company's strategy is to develop these products through 'proof of principle' clinical testing, and then secure partners for late stage development, sales and marketing. Laboratory, manufacturing and clinical work is outsourced to selected specialists, operating under expert in-house management. This operational structure allows access to the best external research facilities whilst maintaining low fixed overheads and a lower development cost structure.


Cogane(tm)

Cogane(tm) (PYM50028) is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily crosses the blood brain barrier. In pre-clinical studies, Cogane(tm) stimulates the release of neuronal growth factors, increases neurite outgrowth and protects against neuronal degeneration. Importantly, Cogane(tm) also reverses the decrease of neuronal growth factors and reverses dopaminergic neuronal degeneration observed in vitro. When administered orally to pre-clinical models of Parkinson's disease, Cogane(tm) reverses the loss of dopaminergic neurones.

*Movement Disorders (2007) Vol 22 (Suppl 16): page S18, abstract number 58.

Parkinson's disease

Parkinson's disease is a movement disorder characterised by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the result of altered signaling of an area of the brain, the striatum, responsible for the control of movement. This is caused by degeneration of dopaminergic neurones between the striatum and the substantia nigra part of the brain leading to insufficient formation and action of dopamine. Parkinson's disease is therefore termed a neurodegenerative disease. The disease is slow in onset and the appearance of symptoms reflects the gradual loss of dopaminergic neurones.


The prevalence of the disease is estimat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
(Date:7/31/2015)... , July 31, 2015 The ... press release on July 28, 2015, "Surviving Your ... Launches Fundraising for Patient Safety." A ... sentence should read: "PPAHS is a ... Patients on Opioids. For more information on the National ...
(Date:7/31/2015)... Quietly, sedately, Morocco,s pharmaceutical sector is shining. ... is strong, with a well-developed base of local producers ... One place where the quality of Moroccan pharma ... quietly become the second largest African exporter of drugs ... Moroccan pharma companies have been making inroads as exporters ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... May 2, 2012 Janssen Research & Development, LLC, ... Drug Applications (sNDAs) to the U.S. Food and Drug ... ® (rivaroxaban), an oral anticoagulant, to treat patients ... and prevention of recurrent venous thromboembolism (VTE). ...
... Official journal of the American Association for ... of scientific, technical and medical information products and services, announces ... American Association for Geriatric Psychiatry (AAGP) to publish ... AJGP ) beginning in January 2013. "We are ...
Cached Medicine Technology:Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 2Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 3
(Date:7/31/2015)... , ... July 31, 2015 , ... Ticket Down is ... currently going on in Chicago at Grant Park. The festival will end on ... North America to Chicago for the annual Lollapalooza. This unique and unbelievably popular ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... store run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store ... of which are customizable. The best part: whenever a product is purchased, the ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... 2015 , ... According to the article published July 27 on My News LA, ... and extinguished by the city’s fire department before it caused major damage throughout the building. ... the fire, and it was a fire alarm system that tipped off fire fighters so ...
Breaking Medicine News(10 mins):Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... Journal of Human Nutrition and Dietetics assessed whether ... prevention of prostate cancer. Results suggest that a diet low ... vegetables is beneficial in preventing and treating prostate cancer. ... review of dietary recommendations in the prevention of prostate cancer ...
... , Amazing System will Activate More than 6,000 Contacts at 3,000 ... The following is being issued by New America Media: , , WHO: ... Sandy Close , executive director of New America Media (NAM), an organization representing ... Beverly Thomas , vice president of communications and public affairs for ...
... June 3 RESOLVE : The National Infertility ... of New York) last night with The 2009 Friends ... at Tavern on the Green. This awards program recognizes individuals and ... with infertility. This Night of Hope supports RESOLVE in helping the ...
... Key Motivators for Participation , , , ... Company of America (Guardian), a leading provider of employee ... results of a comprehensive survey on consumers, attitudes and ... and high-deductible health plans (HDHPs). , ...
... N.J., June 3 Quest Diagnostics Incorporated (NYSE: ... and services, announced today that, as of 5:00 p.m., New ... Date"), the following principal amounts of its 5.125% Senior Notes ... "Notes") have been validly tendered and not validly withdrawn in ...
... Carolina Care Plan members can now have fresh organic ... homes through a new partnership with The Chef,s Garden, ... South Carolina restaurants including Charleston Grill and Circa 1886. ... eliminate unhealthy habits and promises to enhance diet and ...
Cached Medicine News:Health News:NAM Launches Emergency Network System to Deliver Disaster Alerts and Health Warnings to Millions in Ethnic Communities 2Health News:National Infertility Organization Honors RMA of New York for Community Support 2Health News:Guardian Survey Reveals Widespread Lack of Understanding of Health Savings Accounts 2Health News:Guardian Survey Reveals Widespread Lack of Understanding of Health Savings Accounts 3Health News:Guardian Survey Reveals Widespread Lack of Understanding of Health Savings Accounts 4Health News:Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 2Health News:Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 3Health News:Carolina Care Plan Launches New Home Delivery Program for Organic Produce 2
... confirmed Atriums superior biocompatibility and strength ... hernia repair. These same studies indicate ... hernia mesh can result in a ... when Atrium first introduced thin wall ...
... Repair Company, we recognize that there are ... tissue in-growth between the prosthesis and the ... Like all the products in Bards complete ... clinically proven, versatile repair.,The Reconix Patch is ...
... In applications such as laparoscopic ... reconstruction, surgeons require a surgical biomaterial ... incorporation.,GORE MYCROMESH Biomaterial provides the answer ... soft tissue reconstructions. Made from strong, ...
... CompanySM is pleased to announce the latest ... Composix E/X mesh.,When Bard Composix mesh was ... ventral hernia repair prosthesis that combined two ... ePTFE, in one product. Bard Composix E/X ...
Medicine Products: